Tasly Pharmaceutical Group Co (SHSE:600535) Ending Cash Position : ¥739 Mil (As of Mar. 2025)

View and export this data going back to 2002. Start your Free Trial

What is Tasly Pharmaceutical Group Co Ending Cash Position?

Tasly Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Mar. 2025 was ¥739 Mil.

Tasly Pharmaceutical Group Co's quarterly Ending Cash Position declined from Sep. 2024 (¥1,021 Mil) to Dec. 2024 (¥817 Mil) and declined from Dec. 2024 (¥817 Mil) to Mar. 2025 (¥739 Mil).

Tasly Pharmaceutical Group Co's annual Ending Cash Position declined from Dec. 2022 (¥2,928 Mil) to Dec. 2023 (¥2,197 Mil) and declined from Dec. 2023 (¥2,197 Mil) to Dec. 2024 (¥817 Mil).

Tasly Pharmaceutical Group Co Ending Cash Position Historical Data

The historical data trend for Tasly Pharmaceutical Group Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tasly Pharmaceutical Group Co Ending Cash Position Chart

Tasly Pharmaceutical Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

1,827.52

2,104.49

2,927.87

2,197.33

817.28

Tasly Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															2,251.99	1,972.22	1,020.57	817.28	738.96

Tasly Pharmaceutical Group Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tasly Pharmaceutical Group Co's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2197.333	+	-1380.049
	=	817

Tasly Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	817.284	+	-78.326
	=	739

Tasly Pharmaceutical Group Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Tasly Pharmaceutical Group Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Tasly Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tasly Pharmaceutical Group Co Ltd (SHSE:600535) » Definitions » Ending Cash Position

Traded in Other Exchanges

N/A

Address

2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410

Website

http://www.tasly.com

Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.

Executives

Wu Nai Feng

Director

Tasly Pharmaceutical Group Co Headlines

No Headlines